Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

Emergency Use Authorization of Veru Inc.'s Sabizabulin for Covid-19 was rejected by the FDA for United States use for now, barring a new study being done for further review at a later time point. Potential remains to still obtain Emergency Use Authorization of Sabizabulin for Covid-19 in other territories outside of the United States.

Veru: Great Potential Despite FDA Rejection Of Sabizabulin EUA

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET.

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

Veru (NASDAQ: VERU ) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment. That rejection has to do with sabizabulin, which is Veru's drug for treating patients in hospitals suffering from severe Covid-19.

Why Is Veru (VERU) Stock Down 37% Today?

Share of Veru Inc. VERU, +0.53% plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company's request for Emergency Use Authorization (EUA) for sabizabulin, its treatment for hospitalized patients with COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). The company said that although the FDA declined the EUA request, “the FDA remains committed to working with the company for the development of sabizabulin.

Veru stock plummets toward 2 1/2-year low after FDA denies EUA request for COVID-19 treatment

MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that the U.S. Food and Drug Administration (FDA) has declined to grant at this time the Company's request for Emergency Use Authorization (EUA) for sabizabulin, Veru's novel microtubule disruptor, to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS).

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

Veru Inc. is eyeing emergency use authorization for its COVID-19 drug Sabizabulin, which is currently under FDA review. Veru Inc. shares fell around 20% to a 52-week low after reporting Q1 FY23 results that fell short of analysts' revenue forecasts.

Veru Inc.: Q1 Revenues Fall Short And Uncertainty Looms, Making It Risky

Veru Inc. (VERU) delivered earnings and revenue surprises of -21.05% and 50.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies

Veru Reports Fiscal 2023 First Quarter Financial Results

New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit.The lawsuit on behalf of Veru investors has been commenced in the the United States District Court for the Southern District of Florida. This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc.

Veru Class Action: Levi & Korsinsky Reminds Veru Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 6, 2023 - VERU

New York, New York--(Newsfile Corp. - February 3, 2023) - Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit.The lawsuit on behalf of Veru investors has been commenced in the the United States District Court for the Southern District of Florida. This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc.

Veru Class Action: Levi & Korsinsky Reminds Veru Inc. Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of February 6, 2023 - VERU

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”).

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)

Los Angeles, California--(Newsfile Corp. - February 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Veru Inc. (NASDAQ: VERU). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/veru-inc-loss-submission-form/?id=36162&from=4 This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.

VERU SHAREHOLDER ALERT: Jakubowitz Law Reminds Veru Shareholders of a Lead Plaintiff Deadline of February 6, 2023

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. ("Veru" or the "Company") (NASDAQ: VERU). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

New York, New York--(Newsfile Corp. - February 2, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, both dates inclusive (the "Class Period"), of the important February 6, 2023 lead plaintiff deadline.

VERU Important Deadline Monday: ROSEN, Leading Investor Counsel, Encourages Veru, Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action - VERU

Los Angeles, California--(Newsfile Corp. - February 2, 2023) - Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU).Class Period: May 11, 2022 - November 9, 2022Lead Plaintiff Deadline: February 6, 2023If you wish to serve as lead plaintiff of the Veru lawsuit, you can submit your contact information at www.glancylaw.com/cases/veru-inc/.

VERU Investors Have Opportunity to Lead Veru Inc. Securities Fraud Lawsuit

Los Angeles, California--(Newsfile Corp. - February 2, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the Firm

San Francisco, California--(Newsfile Corp. - February 2, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - Nov. 9, 2022Lead Plaintiff Deadline: Feb. 6, 2023Visit: www.hbsslaw.com/investor-fraud/VERUContact An Attorney Now: VERU@hbsslaw.com844-916-0895Veru Inc. (NASDAQ: VERU) Securities Fraud Class Action: The complaint alleges that throughout the Class Period, Defendants misrepresented and concealed material adverse facts about the data from

HAGENS BERMAN Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Fraud Lawsuit

NEW YORK , Feb. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Veru investors who were adversely affected by alleged securities fraud.

VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Los Angeles, California--(Newsfile Corp. - February 1, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 1, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Veru Inc.. Shareholders who purchased shares of VERU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Veru Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 6, 2023 - (NASDAQ: VERU)

Did you lose money on investments in Veru?  If so, please visit Veru Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

VERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU)

San Francisco, California--(Newsfile Corp. - January 31, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - Nov. 9, 2022Lead Plaintiff Deadline: Feb. 6, 2023Visit: www.hbsslaw.com/investor-fraud/VERU Contact An Attorney Now: VERU@hbsslaw.com 844-916-0895Veru Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Veru Inc. (VERU) Investors to Feb. 6th Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm's Attorneys

New York, New York--(Newsfile Corp. - January 31, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, both dates inclusive (the "Class Period"), of the important February 6, 2023 lead plaintiff deadline.

VERU Deadline Notice: ROSEN, Global Investor Counsel, Encourages Veru, Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action - VERU

Los Angeles, California--(Newsfile Corp. - January 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

News for Veru Stock (VERU)